iCAD (NASDAQ:ICAD - Get Free Report) was upgraded by research analysts at StockNews.com from a "sell" rating to a "hold" rating in a research note issued on Thursday.
iCAD Trading Down 4.6 %
Shares of NASDAQ ICAD traded down $0.13 during mid-day trading on Thursday, hitting $2.70. The company had a trading volume of 434,914 shares, compared to its average volume of 799,913. The stock's 50-day moving average price is $2.46 and its 200-day moving average price is $1.93. The company has a market capitalization of $71.66 million, a price-to-earnings ratio of -20.77 and a beta of 1.47. iCAD has a 1 year low of $1.18 and a 1 year high of $3.78.
Institutional Inflows and Outflows
Several institutional investors have recently made changes to their positions in the company. Perritt Capital Management Inc grew its position in iCAD by 1.9% during the fourth quarter. Perritt Capital Management Inc now owns 189,100 shares of the technology company's stock worth $346,000 after buying an additional 3,600 shares in the last quarter. waypoint wealth counsel grew its holdings in shares of iCAD by 44.0% during the fourth quarter. waypoint wealth counsel now owns 14,400 shares of the technology company's stock worth $26,000 after purchasing an additional 4,400 shares in the last quarter. Wells Fargo & Company MN increased its position in shares of iCAD by 51.3% in the fourth quarter. Wells Fargo & Company MN now owns 39,542 shares of the technology company's stock worth $72,000 after purchasing an additional 13,402 shares during the last quarter. Thompson Davis & CO. Inc. purchased a new stake in iCAD in the fourth quarter valued at approximately $31,000. Finally, Geode Capital Management LLC lifted its position in iCAD by 6.6% during the fourth quarter. Geode Capital Management LLC now owns 276,493 shares of the technology company's stock valued at $506,000 after purchasing an additional 17,059 shares during the last quarter. Institutional investors own 24.61% of the company's stock.
About iCAD
(
Get Free Report)
iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.
Featured Articles
Before you consider iCAD, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and iCAD wasn't on the list.
While iCAD currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
